17 results
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
clearance by the FDA in April 2024
Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors
BRISBANE, Calif., June 18, 2024 – Day … by the opportunity presented by DAY301, and we believe we have the right team in place to develop the program to its full potential.”
DAY301 targets PTK7
S-8
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
4 Jan 24
Registration of securities for employees
4:06pm
capital targets and changes in working capital; and
(tt) any other metric that is capable of measurement as determined by the Committee.
The Committee
S-8
EX-99.1
xem1nviq3i wwd18
31 Oct 22
Registration of securities for employees
4:07pm
10-K
wydymhfsg
7 Mar 22
Annual report
7:36am
424B4
nore5qm bhbj
27 May 21
Prospectus supplement with pricing info
4:18pm
S-1/A
3slu nsb27o
24 May 21
IPO registration (amended)
6:16am
S-1/A
EX-10.2
sf9 pix9tr
24 May 21
IPO registration (amended)
6:16am
S-1
EX-10.5
u463mgw
4 May 21
IPO registration
4:12pm
S-1
EX-10.2
dma k9mpkd27rv
4 May 21
IPO registration
4:12pm
S-1
EX-10.6
rbi9xv v32lnhrl
4 May 21
IPO registration
4:12pm
S-1
qvbntnxa
4 May 21
IPO registration
4:12pm
DRS
c0yj3d2nlv4k2bg
19 Mar 21
Draft registration statement
12:00am
- Prev
- 1
- Next